ABIONYX Pharma SA (EPA:ABNX)

ABIONYX Pharma Statistics

Total Valuation

ABIONYX Pharma has a market cap or net worth of EUR 98.82 million. The enterprise value is 99.10 million.

Market Cap	98.82M
Enterprise Value	99.10M

Important Dates

The next confirmed earnings date is Thursday, September 24, 2026.

Earnings Date	Sep 24, 2026
Ex-Dividend Date	n/a

Share Statistics

ABIONYX Pharma has 35.29 million shares outstanding. The number of shares has increased by 3.73% in one year.

Current Share Class	35.29M
Shares Outstanding	35.29M
Shares Change (YoY)	+3.73%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	35.78%
Owned by Institutions (%)	4.30%
Float	19.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	24.32
PB Ratio	21.90
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-17.86
EV / Sales	24.39
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-31.21

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.84.

Current Ratio	1.06
Quick Ratio	0.99
Debt / Equity	0.84
Debt / EBITDA	n/a
Debt / FCF	-1.20
Interest Coverage	-65.15

Financial Efficiency

Return on equity (ROE) is -92.29% and return on invested capital (ROIC) is -115.47%.

Return on Equity (ROE)	-92.29%
Return on Assets (ROA)	-25.97%
Return on Invested Capital (ROIC)	-115.47%
Return on Capital Employed (ROCE)	-69.64%
Weighted Average Cost of Capital (WACC)	7.23%
Revenue Per Employee	82,918
Profits Per Employee	-113,265
Employee Count	51
Asset Turnover	0.30
Inventory Turnover	15.15

Taxes

In the past 12 months, ABIONYX Pharma has paid 9,000 in taxes.

Income Tax	9,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +112.48% in the last 52 weeks. The beta is 0.58, so ABIONYX Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.58
52-Week Price Change	+112.48%
50-Day Moving Average	3.48
200-Day Moving Average	3.60
Relative Strength Index (RSI)	23.65
Average Volume (20 Days)	154,645

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABIONYX Pharma had revenue of EUR 4.06 million and -5.55 million in losses. Loss per share was -0.16.

Revenue	4.06M
Gross Profit	534,000
Operating Income	-5.54M
Pretax Income	-5.54M
Net Income	-5.55M
EBITDA	-5.42M
EBIT	-5.54M
Loss Per Share	-0.16

Balance Sheet

The company has 3.52 million in cash and 3.81 million in debt, with a net cash position of -284,000 or -0.01 per share.

Cash & Cash Equivalents	3.52M
Total Debt	3.81M
Net Cash	-284,000
Net Cash Per Share	-0.01
Equity (Book Value)	4.51M
Book Value Per Share	0.13
Working Capital	304,000

Cash Flow

In the last 12 months, operating cash flow was -2.93 million and capital expenditures -242,000, giving a free cash flow of -3.18 million.

Operating Cash Flow	-2.93M
Capital Expenditures	-242,000
Depreciation & Amortization	115,000
Net Borrowing	-429,000
Free Cash Flow	-3.18M
FCF Per Share	-0.09

Margins

Gross margin is 13.14%, with operating and profit margins of -136.30% and -136.60%.

Gross Margin	13.14%
Operating Margin	-136.30%
Pretax Margin	-136.38%
Profit Margin	-136.60%
EBITDA Margin	-133.47%
EBIT Margin	-136.30%
FCF Margin	n/a

Dividends & Yields

ABIONYX Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.73%
Shareholder Yield	-3.73%
Earnings Yield	-5.62%
FCF Yield	-3.21%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABIONYX Pharma has an Altman Z-Score of 3.62 and a Piotroski F-Score of 3.

Altman Z-Score	3.62
Piotroski F-Score	3